<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013269</url>
  </required_header>
  <id_info>
    <org_study_id>ACYSS</org_study_id>
    <secondary_id>DRKS00015483</secondary_id>
    <nct_id>NCT04013269</nct_id>
  </id_info>
  <brief_title>Adjuvant Therapy With CytoSorb in Refractory Septic Shock</brief_title>
  <acronym>ACYSS</acronym>
  <official_title>Effect of the CytoSorb Adsorber on Hemodynamic, Immunological and Pharmacokinetic Parameters in Refractory Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized single center study investigates to what extent the removal of
      elevated cytokine levels by hemoadsorption has a positive effect on the treatment of patients
      in septic shock by stabilizing the circulatory situation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The term &quot;sepsis&quot; refers to a clinical syndrome in which a dysregulation of the host's
      inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis
      and septic shock are major causes of death in intensive care units worldwide.

      The clinical picture of septic shock, the most severe form of sepsis, leads to uncontrolled
      production and release of a large number of proinflammatory cytokines and mediators, the
      &quot;cytokine storm&quot;. Septic shock is accompanied by a massive increase in mortality of up to
      60%.

      This high mortality rate is due to a lack of current treatment options. The early recognition
      of the disease and its immediate treatment are decisive for successful therapy and the
      survival of those affected. The most important therapeutic steps, apart from focus control by
      antibiotics and surgical intervention, are the stabilization of the affected organ systems,
      in particular the circulatory system and the respiratory system. As an extracorporeal and
      non-specific procedure for the interruption of the cytokine storm, hemoadsorption by means of
      CytoSorb adsorbers may be an intervention, which has already demonstrated its basic
      effectiveness in the treatment of septic and cardiosurgical patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a reduction of catecholamine dose of at least 25% within the first 48 hours of treatment</measure>
    <time_frame>48 hours</time_frame>
    <description>Percentage of patients with a reduction of catecholamine dose of at least 25% compared to baseline for at least 6 hours within the first 48 hours of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in organ dysfunction</measure>
    <time_frame>10 days</time_frame>
    <description>Change in organ dysfunction based on &quot;Sequential Organ Failure Assessment&quot; (SOFA) Score The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables were collected serially every 24 hours of a patient's ICU admission. The &quot;worst&quot; measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate clearance</measure>
    <time_frame>10 days</time_frame>
    <description>Improving lactate clearance by lowering serum lactate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>10 days</time_frame>
    <description>Time with need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a reduction of catecholamine dose of at least 25% within the first 24 hours of treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of patients with a reduction of catecholamine dose of at least 25% compared to baseline for at least 6 hours within the first 48 hours of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of septic shock</measure>
    <time_frame>10 days</time_frame>
    <description>Time until shock resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>90 days</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation</measure>
    <time_frame>10 days</time_frame>
    <description>Time on mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative catecholamine dose</measure>
    <time_frame>10 days</time_frame>
    <description>Cumulative catecholamine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and ICU mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Overall and ICU mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of administered anti-infectives</measure>
    <time_frame>3 days</time_frame>
    <description>Serum drug Levels of pre and post filter and adsorber system on day 1-3 while CytoSorb therapy (sampling: t 0, 1, 2, 6, 8, 12, 24 h after CytoSorb initiation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma Interleukin-6 (IL6) level</measure>
    <time_frame>10 days</time_frame>
    <description>Change of plasma Interleukin-6 (IL6) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma Interleukin-10 (IL10) level</measure>
    <time_frame>10 days</time_frame>
    <description>Change of plasma Interleukin-10 (IL10) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma Procalcitonin (PCT) level</measure>
    <time_frame>10 days</time_frame>
    <description>Change of plasma Procalcitonin (PCT) level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HLA-DR level</measure>
    <time_frame>10 days</time_frame>
    <description>Change of HLA-DR (Human Leukocyte Antigen - DR isotype) level of monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of TNF alpha level after ex-vivo stimulation</measure>
    <time_frame>10 days</time_frame>
    <description>Change of TNF-alfa level (Tumor Necrosis Factor alpha) level after LPS (Lipopolysaccharides) stimulation as sign of monocytic immunocompetence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>CytoSorb-Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb-Therapy</intervention_name>
    <description>Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy</description>
    <arm_group_label>CytoSorb-Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory septic shock

          -  Need for Norepinephrine ≥ 0.25 µg/kg/min

          -  IL6 ≥ 1000 ng/l

          -  Indication for CRRT

        Exclusion Criteria:

          -  Sepsis due to pulmonary or urogenital causes

          -  Onset of septic shock longer than 36 hours

          -  Liver cirrhosis Child Pugh C

          -  &quot;do not resuscitate&quot;-order

          -  expected survival &lt; 14 days

          -  participation in another interventional trial

          -  Pregnancy or breastfeeding

          -  Lack of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominik Jarczak, MD</last_name>
    <phone>+49 40 741035315</phone>
    <email>d.jarczak@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Axel Nierhaus, MD</last_name>
    <phone>+49 40 741035315</phone>
    <email>nierhaus@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Jarczak, MD</last_name>
      <phone>+49 40 741035315</phone>
      <email>d.jarczak@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Axel Nierhaus, MD</last_name>
      <phone>+49 40 741035315</phone>
      <email>nierhaus@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Kluge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominik Jarczak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel Nierhaus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina König, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Taeb AM, Hooper MH, Marik PE. Sepsis: Current Definition, Pathophysiology, Diagnosis, and Management. Nutr Clin Pract. 2017 Jun;32(3):296-308. doi: 10.1177/0884533617695243. Epub 2017 Mar 17. Review.</citation>
    <PMID>28537517</PMID>
  </reference>
  <reference>
    <citation>Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. 2017 Sep;20(3):252-259. doi: 10.1007/s10047-017-0967-4. Epub 2017 Jun 6.</citation>
    <PMID>28589286</PMID>
  </reference>
  <reference>
    <citation>Garau I, März A, Sehner S, Reuter DA, Reichenspurner H, Zöllner C, Kubitz JC. Hemadsorption during cardiopulmonary bypass reduces interleukin 8 and tumor necrosis factor α serum levels in cardiac surgery: a randomized controlled trial. Minerva Anestesiol. 2019 Jul;85(7):715-723. doi: 10.23736/S0375-9393.18.12898-7. Epub 2018 Nov 22.</citation>
    <PMID>30481999</PMID>
  </reference>
  <reference>
    <citation>Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017 Mar 27;21(1):74. doi: 10.1186/s13054-017-1662-9.</citation>
    <PMID>28343448</PMID>
  </reference>
  <reference>
    <citation>Bayer O, Reinhart K, Kohl M, Kabisch B, Marshall J, Sakr Y, Bauer M, Hartog C, Schwarzkopf D, Riedemann N. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med. 2012 Sep;40(9):2543-51.</citation>
    <PMID>22903091</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 15, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Critically ill</keyword>
  <keyword>Intensive care medicine</keyword>
  <keyword>CytoSorb</keyword>
  <keyword>Hemoadsorption</keyword>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

